Scholarlink

<p>Enhancer of zeste homologue 2 (EZH2), as a key histone methyltransferase, is elevated in multiple malignant tumours, which leads to poor prognosis. However, the underlying mechanisms for mediation of EZH2 enzyme activity remain elusive. Here, we report that PRMT6 asymmetrically dimethylates EZH2 at R509 to promote the bindings between EZH2 and other core component of the polycomb repressive complex 2 (PRC2), which enhances PRC2 induced methylation of histone H3 at K27. EZH2 R509 methylation blocks the expression of PRC2 target genes, leading to breast tumorigenesis in vitro and in vivo. Combination of PRMT6 inhibitor EPZ020411, and EZH2 inhibitor GSK126 effectively suppresses breast tumour growth in the mouse xenografts. Furthermore, immunohistochemical analyses demonstrate there is a positive correlation between PRMT6 and meR509-EZH2 expression in the breast cancer tissues. Consistently, PRMT6 mediated EZH2 R509 methylation is also confirmed in PRMT6-knockout mice. Our findings reveal that PRMT6 inhibitors might be promising combination therapy for EZH2-targeting cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PRMT6-mediated EZH2 arginine methylation is critical for breast cancer development

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月19日

查看全文
  • Xue Han,
  • Maoxiang Zhang,
  • Chao Lu,
  • Hui Xu,
  • Shiyu Du,
  • Chenjing Yue,
  • Zhenhai Yu

摘要

Enhancer of zeste homologue 2 (EZH2), as a key histone methyltransferase, is elevated in multiple malignant tumours, which leads to poor prognosis. However, the underlying mechanisms for mediation of EZH2 enzyme activity remain elusive. Here, we report that PRMT6 asymmetrically dimethylates EZH2 at R509 to promote the bindings between EZH2 and other core component of the polycomb repressive complex 2 (PRC2), which enhances PRC2 induced methylation of histone H3 at K27. EZH2 R509 methylation blocks the expression of PRC2 target genes, leading to breast tumorigenesis in vitro and in vivo. Combination of PRMT6 inhibitor EPZ020411, and EZH2 inhibitor GSK126 effectively suppresses breast tumour growth in the mouse xenografts. Furthermore, immunohistochemical analyses demonstrate there is a positive correlation between PRMT6 and meR509-EZH2 expression in the breast cancer tissues. Consistently, PRMT6 mediated EZH2 R509 methylation is also confirmed in PRMT6-knockout mice. Our findings reveal that PRMT6 inhibitors might be promising combination therapy for EZH2-targeting cancer.